Add to Favorites
Test Description

Probes: MET (7q31) | Centromere 7
Disease(s): Multiple solid tumor cancers including lung (NSCLC), gastric, esophageal, endometrial

Clinical Significance

MET gene amplification, as detected by FISH, is one mechanism of MET overexpression. MET amplifications are detected in 3-7% of non-small cell lung cancer (NSCLC) and associated with resistance to EGFR inhibitors and shorter survival in this disease. MET amplifications are also detected in a wide variety of other solid tumors including gastric (up to 10%), esophageal (4%), and endometrial tumors. Clinical trials have demonstrated activity of MET inhibitors against numerous solid tumors such as lung, breast, melanoma, liver, prostate, renal, and ovarian, including tumor reduction in NSCLC and breast cancer patients who had developed resistance to EGFR inhibitors.

Specimen Requirements
  • Bone marrow aspirate: N/A
  • Peripheral blood: N/A
  • Fresh, unfixed tissue: N/A
  • Fluids: N/A
  • Paraffin block: Send paraffin block. Also send circled H&E slide for tech-only (required).
  • Cut slides: H&E slide (required) plus 4 unstained slides cut at 4-5 microns. Circle H&E slide for tech-only.
Storage and Transportation

Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.

CPT Code(s)*
88377x1 manual or 88374x1 automated.
New York Approved
Level of Service
Turnaround Time

7 days

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.